Novel protective properties of auranofin: Inhibition of human astrocyte cytotoxic secretions and direct neuroprotection

Life Sciences

Volumn 92, Issue 22, 2013, Pages 1072-1080

  Madeira, J M ^a   Renschler, C J ^a   Mueller, B ^a   Hashioka, S ^a   Gibson, D L ^a   Klegeris, A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Astrocytes; Brain; Gold compounds; Heme oxygenase (HOX 1); Neurodegenerative diseases; Neurotoxicity

Indexed keywords

AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AUROTHIOSULPHATE; CYTOTOXIN; GOLD DERIVATIVE; HEME OXYGENASE 1; HYDROGEN PEROXIDE; INTERLEUKIN 6; INTERLEUKIN 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; CYTOKINE RELEASE; CYTOTOXICITY; DEGENERATIVE DISEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LASER SURGERY; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; RECEPTOR UPREGULATION; SUPERNATANT;

ANIMALS; ANTIRHEUMATIC AGENTS; ASTROCYTES; AURANOFIN; BRAIN; CELL LINE; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; FEMALE; HEME OXYGENASE (DECYCLIZING); HUMANS; HYDROGEN PEROXIDE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; OXIDANTS; OXIDATIVE STRESS; UP-REGULATION;

MUS;

EID: 84878220183     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.04.005     Document Type: Article

References (57)

1. T. Ashino, J. Sugiuchi, J. Uehara, Y. Naito-Yamamoto, S. Kenmotsu, and Y. Iwakura Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1 J Toxicol Sci 36 2011 635 643
2. F.A. Azevedo, L.R. Carvalho, L.T. Grinberg, J.M. Farfel, R.E. Ferretti, and R.E. Leite Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain J Comp Neurol 513 2009 532 541
3. M. Belanger, and P.J. Magistretti The role of astroglia in neuroprotection Dialogues Clin Neurosci 11 2009 281 295
4. M.L. Block, L. Zecca, and J.S. Hong Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat Rev Immunol 8 2007 57 69
5. K. Blocka Auranofin versus injectable gold. Comparison of pharmacokinetic properties Am J Med 75 1983 114 122
6. M. Bruze, B. Bjorkner, and H. Moller Skin testing with gold sodium thiomalate and gold sodium thiosulfate Contact Dermatitis 32 1995 5 8
7. S.A. Bustin, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, and M. Kubista The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments Clin Chem 55 2009 611 622
8. B. Cameron, and G.E. Landreth Inflammation, microglia, and Alzheimer's disease Neurobiol Dis 37 2010 503 509
9. G.D. Champion, G.G. Graham, and J.B. Ziegler The gold complexes Baillieres Clin Rheumatol 4 1990 491 534
10. W.L. Chien, T.R. Lee, S.Y. Hung, K.H. Kang, M.J. Lee, and W.M. Fu Impairment of oxidative stress-induced heme oxygenase-1 expression by the defect of Parkinson-related gene of PINK1 J Neurochem 117 2011 643 653
11. A. Cuadrado, and A.I. Rojo Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections Curr Pharm Des 14 2008 429 442
12. A.E. Finkelstein, F.R. Roisman, V. Batista, F.G. de Nudelman, E.H. de Titto, and M. Mizraji Oral chrysotherapy in rheumatoid arthritis: minimum effective dose J Rheumatol 7 1980 160 168
13. E.M. Frohman, M.K. Racke, and C.S. Raine Multiple sclerosis - the plaque and its pathogenesis N Engl J Med 354 2006 942 955
14. C.J. Garwood, A.M. Pooler, J. Atherton, D.P. Hanger, and W. Noble Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture Cell Death Disord 2 2011 e167
15. A. Glennas, T.K. Kvien, O. Andrup, O. Clarke-Jenssen, B. Karstensen, and U. Brodin Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis Br J Rheumatol 36 1997 870 877
16. G.G. Graham, and M.M. Dale The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. II. Evidence for the formation and biological activity of aurocyanide Biochem Pharmacol 39 1990 1697 1702
17. G.G. Graham, G.D. Champion, and J.B. Ziegler The cellular metabolism and effects of the gold complexes Met Based Drugs 1 1994 395 404
18. S.S. Gunatilleke, J.A. McCammon, A.M. Barrios, and C.A. de Oliveira Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study J Biol Inorg Chem 13 2008 555 561
19. M.B. Hansen, S.E. Nielsen, and K. Berg Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill J Immunol Methods 119 1989 203 210
20. S. Hashioka, A. Klegeris, and P.L. McGeer Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity Exp Neurol 217 2009 177 183
21. S. Hashioka, A. Klegeris, C. Schwab, and P.L. McGeer Interferon-gamma- dependent cytotoxic activation of human astrocytes and astrocytoma cells Neurobiol Aging 30 2009 1924 1935
22. S. Hashioka, A. Klegeris, and P.L. McGeer Proton pump inhibitors reduce interferon-gamma-induced neurotoxicity and STAT3 phosphorylation of human astrocytes Glia 59 2011 833 840
23. F. Hayashi, T.K. Means, and A.D. Luster Toll-like receptors stimulate human neutrophil function Blood 102 2003 2660 2669
24. M. Jana, J.A. Anderson, R.N. Saha, X. Liu, and K. Pahan Regulation of inducible nitric oxide synthase in proinflammatory cytokine-stimulated human primary astrocytes Free Radic Biol Med 38 2005 655 664
25. R.E. Kast Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drug Cent Eur Neurosurg 71 2010 139 142
26. W.F. Kean Intramuscular versus oral gold therapy Baillieres Clin Rheumatol 4 1990 219 246
27. W.F. Kean, L. Hart, and W.W. Buchanan Auranofin Br J Rheumatol 36 1997 560 572
28. W.F. Kean, and I.R. Kean Clinical pharmacology of gold Inflammopharmacology 16 2008 112 125
29. N.H. Kim, M.Y. Lee, S.J. Park, J.S. Choi, M.K. Oh, and I.S. Kim Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3 Immunology 122 2007 607 614
30. N.H. Kim, M.K. Oh, H.J. Park, and I.S. Kim Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation J Pharmacol Sci 113 2010 246 254
31. P.J. Kingham, and J.M. Pocock Microglial secreted cathepsin B induces neuronal apoptosis J Neurochem 76 2001 1475 1484
32. A. Klegeris, C.J. Bissonnette, and P.L. McGeer Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor Br J Pharmacol 139 2003 775 786
33. S. Kocanova, E. Buytaert, J.Y. Matroule, J. Piette, J. Golab, and P. de Witte Induction of heme-oxygenase 1 requires the p38MAPL and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy Apoptosis 12 2007 731 741
34. D. Krause, H.S. Suh, L. Tarassishin, Q.L. Cui, B.A. Durafourt, and S.C. Lee The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1 Am J Pathol 179 2011 1360 1372
35. Y.J. Lee, S.B. Han, S.Y. Nam, K.W. Oh, and J.T. Hong Inflammation and Alzheimer's disease Arch Pharm Res 33 2010 1539 1556
36. C. Li, R. Zhao, K. Gao, Z. Wei, M.Y. Yin, and A.C. Hoi Yu Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease Curr Alzheimer Res 8 2011 67 80
37. J.M. Madeira, N. Beloukhina, K. Boudreau, T.A. Boettcher, L. Gurley, and A. Klegeris Cobalt(II) beta-ketoaminato complexes as novel inhibitors of neuroinflammation Eur J Pharmacol 676 2012 81 88
38. J.M. Madeira, D.L. Gibson, W.F. Kean, and A. Klegeris The biological activity of auranofin: implications for novel treatment of diseases Inflammopharmacology 20 2012 297 306
39. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55 63
40. R.E. Mrak, and W.S. Griffin Glia and their cytokines in progression of neurodegeneration Neurobiol Aging 26 2005 349 354
41. A. Nakaya, M. Sagawa, A. Muto, H. Uchida, Y. Ikeda, and M. Kizaki The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity Leuk Res 35 2011 243 249
42. B. Pakkenberg, and H.J. Gundersen Total number of neurons and glial cells in human brain nuclei estimated by the disector and the fractionator J Microsc 150 1988 1 20
43. K.A. Papp, and N.H. Shear Systemic gold therapy Clin Dermatol 9 4 1991 535 551
44. F.R. Roisman, D.T. Walz, and A.E. Finkelstein Superoxide radical production by human leukocytes exposed to immune complexes: inhibitory action of gold compounds Inflammation 7 1983 355 362
45. K. Saijo, and C.K. Glass Microglial cell origin and phenotypes in health and disease Nat Rev Immunol 11 2011 775 787
46. F. Shabani, J. McNeil, and L. Tippett The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs Free Radic Res 28 1998 115 123
47. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1990 1107 1112
48. J.A. Smith, A. Das, S.K. Ray, and N.L. Banik Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases Brain Res Bull 87 2012 10 20
49. I. Stern, J.C. Wataha, J.B. Lewis, R.L. Messer, P.E. Lockwood, and W.Y. Tseng Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion Toxicol In Vitro 19 2005 365 371
50. C.M. Vos, L. Sjulson, A. Nath, J.C. McArthur, C.A. Pardo, and J. Rothstein Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures Exp Neurol 163 2000 324 330
51. D.T. Walz, M.J. Dimartino, D.E. Griswold, A.P. Intoccia, and T.L. Flanagan Biologic actions and pharmaco kinetic studies of auranofin Am J Med 75 1983 90 108
52. D.T. Walz, M.J. Dimartino, and D.E. Griswold The pharmacological profile of auranofin, an orally active gold compound Scand J Rheumatol 12 1983 16 25
53. N. Yamamoto, Y. Izumi, T. Matsuo, S. Wakita, T. Kume, and Y. Takada-Takatori Elevation of heme oxygenase-1 by proteasome inhibition affords dopaminergic neuroprotection J Neurosci Res 88 2010 1934 1942
54. M. Yamashita, H. Niki, M. Yamada, M. Watanabe-Kobayashi, S. Mue, and K. Ohuchi Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages Eur J Pharmacol 325 1997 221 227
55. W. Zhang, T. Wang, Z. Pei, D.S. Miller, X. Wu, and J. Zhang Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease FASEB J 19 2005 533 542
56. N. Zilka, Z. Kazmerova, S. Jadhav, P. Neradil, A. Madari, and M. Novak Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways J Neuroinflammation 9 2012 47
57. M. Zoriy, A. Matuschb, T. Sprussc, and J.S. Becker Laser ablation inductively coupled plasma mass spectrometry for imaging of copper, zinc, and platinum in thin sections of a kidney from a mouse treated with cis-platin Int J Mass Spectrom 260 2007 102-6